Errata (DOI:10.1016/S1470-2045(09)70284-0);Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

The Lancet Oncology

Volumn 11, Issue 1, 2010, Pages 29-37

  Rajkumar, S Vincent ^a   Jacobus, Susanna ^b   Callander, Natalie S ^c   Fonseca, Rafael ^d   Vesole, David H ^e   Williams, Michael E ^f   Abonour, Rafat ^g   Siegel, David S ^h   Katz, Michael ⁱ   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d MAYO CLINIC   (United States)

^e St Vincent's Hospital   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ International Myeloma Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; LENALIDOMIDE; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; WEAKNESS;

EID: 73249146496     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70394-8     Document Type: Erratum

References (28)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 335 (1996) 91-97
3. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
4. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
5. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
6. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
7. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 (2006) 3458-3464
8. Barlogie B., Smith L., and Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310 (1984) 1353-1356
9. Alexanian R., Dimopoulos M.A., Delasalle K., and Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80 (1992) 887-890
10. Rajkumar S.V., Blood E., Vesole D.H., Fonseca R., and Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
11. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
12. Facon T., Mary J.-Y., Pegourie B., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
13. Rajkumar S.V., Rosiñol L., Hussein M., et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26 (2008) 2171-2177
14. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
15. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
16. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
17. Zonder J.A., Crowley J., Hussein M.A., et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Ann Meeting Abstr 110 (2007) A77
18. Rajkumar S.V., and Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354 (2006) 2080
19. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 102 (1998) 1115-1123
20. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (2008) 906-917
21. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
22. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
23. Lacy M.Q., Gertz M.A., Dispenzieri A.A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
24. Niesvizky R., Jayabalan D.S., Christos P.J., et al. BiRD (Biaxin(R)[clarithromycin]/Revlimid(R)[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111 (2007) 1101-1109
25. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21 (2007) 2035-2042
26. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 (2008) 414-423
27. Kapoor P., Kumar S., Fonseca R., et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114 (2009) 518-521
28. San Miguel J.F., Dimopoulos M., Weber D., et al. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis). ASH Ann Meeting Abstr 110 (2007) A2712 (abstr).